Sarepta Therapeutics
Overview and Explanation of Company
AVI Bio Pharma Inc. is a medical research and drug devlopment company located in Portland Oregon. It was incorporated in 1980. Its primary products in development rely on NeuGene, a Morpholino drug. AVI Bio Pharam Inc. is allied with the companies Exelixis Inc., DepoMed Inc, XTL Biopharmaceuticals Ltd., Abgenix inc., and SuperGen, Inc. They have conducted six humant trials for their cancer vaccine AVICINE, working on collorectal and pancreatic cancers. Their drug NeuGene has been tested in conjunction with West Nile Virus, SARS, Hepatitis C and Calicivirus, all of which are single standed RNA viruses.
Key Statistics
Market Cap (intraday): 97.65M,Enterprise Value (29-Sep-05)3: 66.79M, Trailing P/E (ttm, intraday): N/A, Forward P/E (fye 31-Dec-06) 1: N/A, PEG Ratio (5 yr expected): N/A, Price/Sales (ttm): 261.09, Price/Book (mrq): 2.56, Enterprise Value/Revenue (ttm)3: 176.10, Enterprise Value/EBITDA (ttm)3: -3.556
FINANCIAL HIGHLIGHTS
Fiscal Year Fiscal Year Ends: 31-Dec Most Recent Quarter (mrq): 30-Jun-05 Profitability Profit Margin (ttm): -5413.09% Operating Margin (ttm): -5472.21% Management Effectiveness Return on Assets (ttm): -32.97% Return on Equity (ttm): -55.04% Income Statement Revenue (ttm): 379.25K Revenue Per Share (ttm): 0.01 Qtrly Revenue Growth (yoy): 8.40% Gross Profit (ttm): 969.87K EBITDA (ttm): -18.78M Net Income Avl to Common (ttm): -20.53M Diluted EPS (ttm): -0.52 Qtrly Earnings Growth (yoy): -31.00%
Balance Sheet
Total Cash (mrq): 32.19M Total Cash Per Share (mrq): 0.728 Total Debt (mrq): 0 Total Debt/Equity (mrq): 0 Current Ratio (mrq): 16.833 Book Value Per Share (mrq): 0.874 Cash Flow Statement From Operations (ttm): -18.15M Free Cashflow (ttm): -12.69M
Key Executives & Pay Exercised
- Dr. Denis R. Burger Ph.D., 61
Chairman, Chief Exec. Officer and Member of Exec. Committee $ 450.00K $ 0
- Mr. Alan P. Timmins , 45
Pres, Chief Operating Officer, Director and Member of Exec. Committee $ 385.00K $ 0
- Mr. Mark M. Webber , 50
Chief Financial Officer, Principal Accounting Officer, Chief Information Officer and Controller $ 250.00K $ 0
- Dr. Patrick L. Iversen Ph.D., 49
Sr. VP of R&D $ 300.00K $ 0
- Dr. Dwight D. Weller Ph.D., 54
Sr. VP of Chemistry and Manufacturing, Director and Member of Exec. Committee $ 250.00K $ 0